



Research Article

ISSN : 2277-3657  
CODEN(USA) : IJPRPM

## ***Do Non-Viral Microorganisms Play a Role in the Aetiology of Human Cancers? A Review***

**Fawaz D Alshammari**

*Department of Clinical Laboratory Science, College of Applied Medical Science, University of Hail, KSA.*

*E-mail: fawazalshammari 2016 @ gmail.com*

---

### **ABSTRACT**

*The role of non-viral microorganisms (NVM) in oncogenesis has been remained as a subject of considerable debate. While Helicobacter pylori has been recognised as a carcinogenic agent, the role of other NVM in cancer has either been ignored or has not well been understood. Despite this, various mechanisms by which NVM might play a role in carcinogenesis included chronic inflammation and disruption of the cell cycle. The role of bacteria, in particular, in carcinogenesis has been increasingly justified. Growing evidence has provided links between human cancers and a diverse range of bacteria, including for example a role in lung cancer for Chlamydomphila pneumoniae and Mycobacterium tuberculosis. Further research into this overlooked area is needed to understand the potential role of the infectious agents in carcinogenesis. The prevention and treatment of infectious diseases due to their microorganisms, by the use of vaccines and anti-microbial agents, may prove useful in the future to combat the increasing number of cancer cases, worldwide. The objective of this review was therefore to provide an update on the potential role of non-virus microbes in cancer.*

**Key words:** *Non-Viral Microorganisms, Human Cancers, Carcinogenic Agent.*

---

### **INTRODUCTION**

Cancer is the uncontrolled proliferation of abnormal cells that leads to a malignant growth, and ultimately severe morbidity and mortality. More than two hundred different cancers have been recognised, and while common, well-defined risk factors included smoking, an unhealthy diet and age [1-3], and infectious agents (mainly viruses) have been linked to over 20% of cancers [4]. Unhealthy diet might be resulted as a change in lifestyle confronting people with the challenge of doubling diseases [5]. In fact, Malignant neoplasms have remained as a leading cause of death worldwide [6]. Viral infection plays a significant role in the aetiology of hepatitis B (HBV) and C (HBC) and they are considered as one of the principal threats to human life and health worldwide [7]. These viruses can establish a chronic liver infection and, in severe cases, a hepatic carcinoma can be resulted [8]. Human papillomavirus (HPV), which is implicated in at least 90% of all cervical cancers, is yet another viral cancer [9].

While viruses are well characterised in carcinogenesis, the role of the other microorganisms has been less clearly understood and has largely been ignored. Several epidemiological studies have been done during the twentieth century and have associated bacteria with cancer [10]. The most significant studies on this potential role came in 1926, when Glover claimed that certain bacteria were consistently isolated from neoplastic tissue [11]. Since then, a diverse range of bacterial species has been isolated from cancers, therefore suggesting a link between bacteria (in particular) and specific types of cancer. Unfortunately, the role of non-viral microorganisms (NVM) in cancer has been still unclear [12], and such a role has been dismissed on the basis of non-cancer associated bacterial growth within tumours [13-15]; obviously, the presence of bacteria within a tumour has not necessarily suggested the causation. There has been increasing evidence suggesting that our own bacterial microflora have likely participated in carcinogenesis [16, 17].

*Helicobacter pylori* is the bacterium that has been most strongly associated with cancer, in this case, gastric carcinoma and lymphoma [4], but increasingly, evidence has suggested that other microorganisms play a role. *Porphyromonas gingivalis*, for example, has been linked to pancreatic cancer – a two-fold increase in the risk of pancreatic cancer has been suggested for those, currently, or previously, infected with this pathogen. Additionally, *Chlamydia trachomatis* DNA has been isolated from 80% of ovarian tissues from women with ovarian epithelial carcinomas, while all control tissue samples were negative for this organism [18]. Furthermore, studies on *Salmonella enterica* serovar *Typhimurium typhi* (the major causative agent of typhoid) suggested a strong link between infection and the advancement of gallbladder cancer [19, 20]. Despite such associations, however, the relationship between bacteria and cancer has still largely been disputed [1].

This review has been devoted to recent studies on the potential role of bacteria and other NVM in cancer, with particular emphasis being given to their role inducing genetic mutations and inflammation.

### **Bacterial Involvement in Carcinogenesis : Proposed Mechanisms**

A variety of bacteria have been hypothesised to induce carcinogenesis via a range of different mechanisms, including, but not limited to, chronic inflammation, disturbance of the eukaryotic cell cycle, induction of immunosuppression, and down-regulation of apoptosis [21, 22].

#### **Chronic inflammation**

In 1863, Virchow proposed that cancer originates at sites of chronic inflammation, and this causal relationship has been getting increasingly accepted [22]. Inflammation leads to the production of a tumour microenvironment rich in white blood cells, and leukocytes generate reactive oxygen species (ROS) and reactive nitrogen species (RNS), which can induce DNA damage in cells. Such damage can lead to the production of an abnormal cell, which may then undergo the proliferation to produce a neoplasm [22].

#### **Disturbance of the cell cycle**

There is increasing evidence to show that several species of bacteria produce toxins that interfere with the cell cycle; such toxins have been termed as cyclomodulins [12]. Cyclomodulins may stimulate or inhibit the cell cycle to result in the altered growth, which can cause the impaired cell cycle, leading to the uncontrolled cellular proliferation, leading to the beginning of tumour growth. Some bacterial products have been proven to stimulate the division of eukaryotic cells. For example, cytotoxic necrotising factors (CNFs) from *Escherichia coli* can lead to the constitutive activation of a common growth signalling pathway [23].

#### **Bacterial metabolites as carcinogens**

Some bacterial metabolites have been also suspected of increasing the risk of cancer. For instance, a few bacteria can metabolise bile salts to produce cytotoxic bile acids, a metabolite that has been thought to promote cellular proliferation. Additionally, bacteria may ferment polysaccharides and glycoproteins to fatty acids, which can alter the membrane structure, and potentially increase the cell proliferation [24], these are the changes which could all induce cancer formation.

#### ***Helicobacter pylori* and its role in gastric carcinogenesis**

The bacterium *Helicobacter pylori* has been implicated in gastric carcinogenesis in various studies [25]. It is a Gram-negative rod-shaped bacterium that is able to colonise the stomach of humans and animals, where it can induce cancer [26]. Persistent *H. pylori* stomach infection by this organism has been associated with chronic inflammation, and the release of ROS and RNS. Its presence is often associated with the elevated blood levels of interleukin (IL-) 8, a pro-inflammatory cytokine [26]. Two independent groups found *H. pylori* antibodies in the sera of a high percentage of patients who went on to develop gastric carcinoma [27, 28], and a six-fold increase in gastric cancer rates have been reported in populations with a high *H. pylori* infection rate [29]. Sasaki *et al.* inoculated Mongolian gerbils with *H. pylori* and examined them for morphological changes occurring in the stomach. Stomach ulcers and severe active chronic gastritis were observed in a high proportion of the gerbils, and 37% developed adenocarcinoma of the stomach [25]. Considering that the Mongolian gerbil is an excellent animal model for the gastric studies, these results were highly suggestive of an involvement of *H. pylori* in gastric carcinogenesis in humans.

While *H. pylori* has been linked to over 60% of all stomach cancers, few infected individuals develop gastric cancer [26], largely because of the occurrence of distinct virulence factors in different strains of the bacterium. Some strains contain the *cagA* pathogenicity island (PAI), a significant virulence factor that induces the activation of mitogen-activated protein kinases (MAPK); the expression of transcription factors *c-fos* and *c-jun*, and simultaneous expression of the encoded proteins increases the cellular proliferation [30]. The affirmation of the engagement of *H.*

*pylori* in gastric cancer should have emphasised the potential role of the other microorganisms in the aetiology of human cancers, but surprisingly, this bacterium has been viewed as an exception, and the role of NVM, in general, has been largely ignored.

### **Lung Cancer**

It has been well known that smoking is the largest risk factor, although other risk factors exist, including air pollution and exposure to asbestos or diesel exhausts [14, 31, 32]. There is also increasing evidence that infection with various bacteria (notably the two species discussed below) may be related to an increased risk of the disease.

#### ***Chlamydia pneumoniae***

Previously known as *Chlamydia pneumoniae* [33] (NCBI, 2009), *C. pneumoniae* is a Gram-negative intracellular bacteria [34] that is transmitted via respiratory secretions and aerosol, and can cause a variety of infections including the chronic obstructive pulmonary disease (COPD), bronchitis and pneumonia. This bacterium appears to persist in the lungs, and induce pulmonary inflammation [34-36]. Research has also suggested an involvement of *C. pneumoniae* in lung cancer. In a 2004 study, which involves 520 individuals with confirmed diagnoses of lung cancer being serologically tested [37], *C. pneumoniae* IgA antibodies were detected at much higher levels in people living with lung cancer compared to the control group. Another study used an alternative serological technique: antibodies complementary to the *Chlamydia* heat shock protein-60 (CHSP-60) were employed as biomarkers for the chronic infection [35]. CHSP-60 has been consistently expressed during persistent infection, and has been an important protein in inflammatory-induced tissue damage. The CHSP-60 enzyme-linked immunosorbent assay (ELISA) used a recombinant *Chlamydia trachomatis* HSP-60 antigen, which shares 90% homology with CHSP-60 from *C. pneumoniae*. Individuals seropositive for CHSP-60 IgG antibodies were shown to have a significantly increased risk of becoming diagnosed with lung cancer in later years of their life.

The marked association between *C. pneumoniae* and lung cancer has been highly suggestive of its role in the aetiology of lung cancer, and the link between chronic infection and inflammation has provided a highly plausible mechanism for such carcinogenesis. Although the relationship between *C. pneumoniae* and the corresponding increased lung cancer risk is somewhat variable, the estimates of an elevated risk of lung cancer due to the presence of this bacterium ranged between 0.7- and 9.0-fold [35].

#### ***Mycobacterium tuberculosis***

*Mycobacterium tuberculosis* has currently infected some 33.3% of the world's population [38]. This intracellular bacterium persists in the lungs [39] and causes symptoms including a cough, fever and weight loss. Chronic inflammation caused by a latent infection triggered by this bacterium has been considered to lead to tissue damage, fibrosis and genetic alterations [38]. Additionally, tuberculosis scars and deforms the blood and lymphatic vessels, which may allow carcinogens to enter the lungs more easily and bring about cancer [40, 41].

Tuberculosis has been associated with a two-fold increase in the risk of lung cancer, and a 3.7-fold increase in the risk of squamous cell carcinoma [38], though some researchers have disputed against such an association [37-41].

### **Oesophageal Cancer**

Two major types of oesophageal cancer exist in squamous cell carcinoma and adenocarcinoma [4]. Squamous cell carcinoma happens more often in the upper and middle regions of the oesophagus, whereas adenocarcinomas tend to occur in the lower region [42]. Risk factors for this type of cancer include smoking, alcohol consumption and a high body mass index (BMI) [43]. It has been suggested that *Campylobacter concisus*, *Campylobacter rectus* and *Streptococcus anginosus* are likely to be involved in carcinogenesis of the oesophagus [4].

#### ***Campylobacter concisus***

*Campylobacter concisus* is a common mouth commensal, which is rarely found in the oesophagus [44] but which has been discovered to play a key role in acute and chronic gastrointestinal diseases [45]. An increase in the occurrence of *C. concisus* in oesophageal biofilms has been reported in those suffering from adenocarcinoma of the oesophagus [44-47].

Macfarlane *et al.* collected oesophageal biopsy and aspirate specimens from 14 individuals diagnosed with gastrointestinal problems; this included seven patients suffering from Barrett's oesophagus (BO), a common precursor of oesophageal adenocarcinoma [46]. Total counts of bacteria in specimens from patients with BO were higher than those from the control group – 18 different bacteria were detected in the control group, compared to 28 in those suffering from BO. High levels of *Campylobacter* species were also found to colonise 57.1% of the patients with BO, while these bacteria colonised none of the control group.

A transcriptomic and proteomic study found that macrophages infected with *C. concisus* assembled the IFI16 inflammasome [45]. The inflammasome is a multiprotein complex that is expressed during the innate immune response, and plays a major role in the inflammation [48]. *Campylobacter concisus* was also found to affect the expression of p53, tumour necrosis factor alpha (TNF $\alpha$ ), and IL-18 in FLO-1 cell lines (immortalised BO epithelial cells) significantly [47]. This study showed that *C. concisus* might stimulate cellular proliferation within the oesophagus by causing a decrease in the expression of p53 (a tumour suppressor protein), and an increase in the expression of both TNF $\alpha$  and IL-18. Evidence has also been found for elevated levels of IL-18 in patients with oesophageal cancer, thereby suggesting a relationship between IL-18 and cancer [49]. While some researchers were convinced of a link between *Campylobacter* infection and oesophageal cancer, others were less convinced of such an association [50].

#### **Streptococcus anginosus**

Evidence provided by a number of studies suggested that *S. anginosus* is involved in early stages of oesophageal cancer, as well as having a potential role in the induction of gastric cancer [51-53]. The *Streptococcus anginosus* (SAG) group of bacteria includes *S. anginosus*, *S. constelatus* and *S. intermedius*. Like *C. concisus*, these microorganisms are commensal pathogens, although they are normally found in the oropharynx and gastrointestinal (GI) tract [54].

Sasaki *et al.* (1998) found that *S. anginosus* DNA was frequently detected in DNA samples from oesophageal and gastric cancers, but not in samples from cancers of the lung, cervix, bowel or bladder. These results were consistent with a previous study that isolated *S. anginosus* DNA in over 20 percent of people living with gastric cancer [51, 52, 55].

In conclusion, the increased abundance of *S. anginosus* in oesophageal biofilms of individuals with gastric and oesophageal cancers was highly suggestive of it playing a role in neoplasia.

#### **Colorectal Cancer**

Age has been the largest risk factor for this type of cancer, with some 90% of those diagnosed being over 60 ; other risk factors have included the lack of exercise, a diet high in red or processed meats, and obesity. *Streptococcus infantarius* has been linked to bowel cancer as an additional risk factor.

#### **Streptococcus infantarius**

*Streptococcus infantarius*, formerly *S. bovis*, has been implicated as the cause of endocarditis, neonatal meningitis and bowel cancer [1, 56-59]. Biarc *et al.* (2004) [56] inoculated male Wistar rats with this bacterium, and colonic mucosa samples were taken. The proteins of each sample were determined, and it was found that proliferation markers, such as a proliferative cell nuclear antigen (PCNA), were increased [56]. The presence of *S. infantarius* may, therefore, change the eukaryotic gene expression and lead to the cellular proliferation within the colon. Gold *et al.* (2004) reported that 28.9% of patients suffering from *S. infantarius* bacteremia were diagnosed with a malignancy within one month of infection [60]. Three patients were diagnosed with colorectal adenocarcinoma while other malignancies, including gallbladder adenocarcinoma, pancreatic adenocarcinoma and ovarian cancer, were detected in the remaining 13 patients. A similar case study detected *S. infantarius* in the stool samples of 48.6% patients with either colorectal cancer or inflammatory bowel disease [61]. A final case study reported 165 cases of colorectal cancer associated with *S. infantarius* bacteremia [62]. Such case studies provided compelling evidence of an association between *S. infantarius* and colorectal cancer. Although the relationship between *S. infantarius* and bowel cancer has been still unknown, it has been widely accepted that physicians should screen patients suffering from *S. infantarius* bacteremia for colorectal cancer [60].

#### **Concluding Remarks**

The role of non-viral microorganisms in the aetiology of human cancers has been overlooked or, where considered, been the subject of considerable controversy. The link between *H. pylori* and gastric cancer is now widely accepted ; there is, therefore, no reason to believe that other NVMs cannot be involved in the development of cancer. Throughout this review, the evidence for the role of a diverse range of microorganisms in carcinogenesis has been discussed. However, despite the accumulating evidence, the connection remains poorly understood. Although signs of bacteria and parasites in cancers have been observed, this does not prove causation, since the microorganisms may readily infect the tumour microenvironment.

Early treatment of the infections may prevent a large proportion of cancers. Considering that at least 20% of cancers have been likely to be caused by the infectious agents [4], the early eradication of such infections may protect against carcinogenesis. For example, *C. pneumoniae* has been commonly treated using tetracyclines and

erythromycin [63]. Treatment of the individuals infected by *C. pneumoniae* using these antibiotics may decrease the prevalence of lung cancer. Additionally, treatment of *T. vaginalis* infection with metronidazole [64] may reduce the number of cervical cancer cases. Furthermore, vaccination would provide an important prospect in the prevention of such infections, which may lead to the reduction in cancer cases [65].

Furthermore, studies and research are needed to gain a full understanding of the role of NVM in cancer development. A subset of cancer researchers should focus solely on the role of these organisms as the infectious agents in carcinogenesis. Given the increasing evidence of a causal link between NVM and cancer, it has been hoped that within the next ten years, the role of these organisms in carcinogenesis would be fully understood and recognised.

## REFERENCES

1. Whitmore SE, Lamont RJ. Oral bacteria and cancer. *PLoS pathogens*, 2014; 10: e1003933.
2. Saeed M, Alshammari FD, Alam MJ, Sarim KM, Ahmad K, Hussain T, Khan M, Kamal MA, Kausar MA, Alkreathy HM. A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer. *Current drug metabolism*, 2018; 19: 798-805.
3. Hussain T, Bajpai S, Saeed M, Moin A, Alafnan A, Khan M, Kamal MA, Ganash M, Ashraf GM. Potentiating Effect of Ethnomedicinal Plants Against Proliferation on Different Cancer Cell Lines. *Current drug metabolism*, 2018; 19: 584-595.
4. Caygill CP, Gatenby PA. Epidemiology of the association between bacterial infections and cancer. In: ed.^eds., *Bacteria and cancer*. Springer, 2012; pp. 1-24.
5. Marzangi A, Ahangarzadeh Rezaei S\*, Ghareagaji Asl R. (2018). "Health literacy and its relation to quality of life in people with heart disease", *International Journal of Pharmaceutical and Phytopharmacological Research*, 8(3), pp.25-32.
6. Saher A., Heba A., Hanan A. (2018). Knowledge, Attitude and Practices of Working Women in Tabuk University Regarding Breast Cancer. *Int. J. Pharm. Res. Allied Sci.*, 2018, 7(3):198-208.
7. Mosaad S. Mohamed, Yasser M. Zohny, Waleed. M. El-Senousy, Asmaa M. Abou El-Elaa, (2018), "Synthesis and Biological Screening of Novel Pyrazoles and their Precursors as Potential Antiviral Agents", *Pharmacophore*, 9(1), 126-139.
8. Myrmel H, Ulvestad E, ÅSJØ B. The hepatitis C virus enigma. *Apmis*, 2009; 117: 427-439.
9. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. *Reviews in medical virology*, 2009; 19: 97-113.
10. Noureen C, Pankaj C, Rushikesh D. The role of bacteria in oral cancer. *Indian Journal of Medical and Paediatric Oncology*, 2010; 31: 126-131.
11. Glover T. Progress in Cancer Research. *Canada Lancet and Practitioner*, 1926; 67.
12. Mager D. Bacteria and cancer: cause, coincidence or cure? A review. *Journal of translational medicine*, 2006; 4: 14.
13. Cummins J, Tangney M. Bacteria and tumours: causative agents or opportunistic inhabitants? *Infectious agents and cancer*, 2013; 8: 11.
14. Ahmad S, Khan MY, Rafi Z, Khan H, Siddiqui Z, Rehman S, Shahab U, Khan MS, Saeed M, Alouffi S. Oxidation, glycation and glycooxidation—the vicious cycle and lung cancer. In: ed.^eds., *Seminars in cancer biology*. Elsevier, 2017.
15. Adnan M, Khan S, Al-Shammari E, Patel M, Saeed M, Hadi S. In pursuit of cancer metastasis therapy by bacteria and its biofilms: History or future. *Medical hypotheses*, 2017; 100: 78-81.
16. Schwabe RF, Jobin C. The microbiome and cancer. *Nature Reviews Cancer*, 2013; 13: 800.
17. Xuan C, Shamonki JM, Chung A, DiNome ML, Chung M, Sieling PA, Lee DJ. Microbial dysbiosis is associated with human breast cancer. *PloS one*, 2014; 9: e83744.
18. Shanmughapriya S, Senthilkumar G, Vinodhini K, Das B, Vasanthi N, Natarajaseenivasan K. Viral and bacterial aetiologies of epithelial ovarian cancer. *European journal of clinical microbiology & infectious diseases*, 2012; 31: 2311-2317.
19. Shukla VK, Singh H, Pandey M, Upadhyay S, Nath G. Carcinoma of the gallbladder—is it a sequel of typhoid? *Digestive diseases and sciences*, 2000; 45: 900-903.

20. Nath G, Singh YK, Kumar K, Gulati AK, Shukla VK, Khanna AK, Tripathi SK, Jain AK, Kumar M, Singh TB. Association of carcinoma of the gallbladder with typhoid carriage in a typhoid endemic area using nested PCR. *The Journal of Infection in Developing Countries*, 2008; 2: 302-307.
21. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. *Journal of internal medicine*, 2000; 248: 171-183.
22. Coussens LM, Werb Z. Inflammation and cancer. *Nature*, 2002; 420: 860.
23. Nougayrède J-P, Taieb F, De Rycke J, Oswald E. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. *Trends in microbiology*, 2005; 13: 103-110.
24. Parsonnet J. Bacterial infection as a cause of cancer. *Environmental health perspectives*, 1995; 103: 263.
25. Sasaki H, Ishizuka T, Muto M, Nezu M, Nakanishi Y, Inagaki Y, Watanabe H, Watanabe H, Terada M. Presence of *Streptococcus anginosus* DNA in esophageal cancer, dysplasia of esophagus, and gastric cancer. *Cancer research*, 1998; 58: 2991-2995.
26. Chang AH, Parsonnet J. Role of bacteria in oncogenesis. *Clinical microbiology reviews*, 2010; 23: 837-857.
27. Nomura A, Stemmermann GN, Chyou P-H, Kato I, Perez-Perez GI, Blaser MJ. *Helicobacter pylori* infection and gastric carcinoma among Japanese Americans in Hawaii. *New England Journal of Medicine*, 1991; 325: 1132-1136.
28. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. *Helicobacter pylori* infection and the risk of gastric carcinoma. *New England Journal of Medicine*, 1991; 325: 1127-1131.
29. Group ES. An international association between *Helicobacter pylori* infection and gastric cancer. *The Lancet*, 1993; 341: 1359-1363.
30. Meyer-ter-Vehn T, Covacci A, Kist M, Pahl HL. *Helicobacter pylori* activates mitogen-activated protein kinase cascades and induces expression of the proto-oncogenes c-fos and c-jun. *Journal of Biological Chemistry*, 2000; 275: 16064-16072.
31. UK CR. cancer Wil, ed.^eds., 2014B.
32. UK CR. Lung cancer risks and causes'. In: ed.^eds., 2014A.
33. Blasi F, Tarsia P, Aliberti S. *Chlamydia pneumoniae*.database TNt. *Chlamydia pneumoniae*. *Clin Microbiol Infect*. 2009 Jan;15(1):29-35. doi: 10.1111/j.1469-0691.2008.02130.x.
34. Kocazeybek B. Chronic *Chlamydia pneumoniae* infection in lung cancer, a risk factor: a case-control study. *Journal of medical microbiology*, 2003; 52: 721-726.
35. Chaturvedi AK, Gaydos CA, Agreda P, Holden JP, Chatterjee N, Goedert JJ, Caporaso NE, Engels EA. *Chlamydia pneumoniae* infection and risk for lung cancer. *Cancer Epidemiology and Prevention Biomarkers*, 2010; 19: 1498-1505.
36. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. *Science*, 1999; 284: 1318-1322.
37. Littman AJ, White E, Jackson LA, Thornquist MD, Gaydos CA, Goodman GE, Vaughan TL. *Chlamydia pneumoniae* infection and risk of lung cancer. *Cancer Epidemiology and Prevention Biomarkers*, 2004; 13: 1624-1630.
38. Shiels MS, Albanes D, Virtamo J, Engels EA. Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention study. *Cancer Epidemiology and Prevention Biomarkers*, 2011; 20: 672-678.
39. Organization WH. Global tuberculosis report 2016. 214 pages
40. Drent M, Wagenaar SS, Mulder PH, Van Velzen-Blad H, Diamant M, Van den Bosch JM. Bronchoalveolar lavage fluid profiles in sarcoidosis, tuberculosis, and non-Hodgkin's and Hodgkin's disease: an evaluation of differences. *Chest*, 1994; 105: 514-519.
41. Cicėnas S, Vencevičius V. Lung cancer in patients with tuberculosis. *World journal of surgical oncology*, 2007; 5: 22.
42. Support MC. Types of oesophageal cancer'. In: ed.^eds., 2012.
43. Kaakoush NO, Castaño-Rodríguez N, Man SM, Mitchell HM. Is *Campylobacter* to esophageal adenocarcinoma as *Helicobacter* is to gastric adenocarcinoma? *Trends in microbiology*, 2015; 23: 455-462.

44. Blackett K, Siddhi S, Cleary S, Steed H, Miller M, Macfarlane S, Macfarlane G, Dillon J. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality? *Alimentary pharmacology & therapeutics*, 2013; 37: 1084-1092.
45. Kaakoush NO, Deshpande NP, Man SM, Burgos-Portugal JA, Khattak FA, Raftery MJ, Wilkins MR, Mitchell HM. Transcriptomic and proteomic analyses reveal key innate immune signatures in the host response to the gastrointestinal pathogen *Campylobacter concisus*. *Infection and immunity*, 2015; 83: 832-845.
46. Macfarlane S, Furrie E, Macfarlane GT, Dillon JF. Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. *Clinical infectious diseases*, 2007; 45: 29-38.
47. Namin BM, Dallal MMS, Daryani NE. The Effect of *Campylobacter concisus* on Expression of IL-18, TNF- $\alpha$  and p53 in Barrett's Cell Lines. *Jundishapur journal of microbiology*, 2015; 8. (12): e26393.
48. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL- $\beta$ . *Molecular cell*, 2002; 10: 417-426.
49. Diakowska D, Markocka-Maczka K, Grabowski K, Lewandowski A. Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. *Exp Oncol*, 2006; 28: 319-22.
50. Amir I, Konikoff FM, Oppenheim M, Gophna U, Half EE. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. *Environmental microbiology*, 2014; 16: 2905-2914.
51. Morita E, Narikiyo M, Yano A, Nishimura E, Igaki H, Sasaki H, Terada M, Hanada N, Kawabe R. Different frequencies of *Streptococcus anginosus* infection in oral cancer and esophageal cancer. *Cancer science*, 2003; 94: 492-496.
52. Sasaki H, Igaki H, Ishizuka T, Kogoma Y, Sugimura T, Terada M. Presence of *Streptococcus* DNA sequence in surgical specimens of gastric cancer. *Cancer Science*, 1995; 86: 791-794.
53. el-Wakil H, Kamel N, Mahmoud M. A preliminary study on the relationship between *Trichomonas vaginalis* and cervical cancer in Egyptian women. *Journal of the Egyptian Society of Parasitology*, 2002; 32: 167-178.
54. Junckerstorff RK, Robinson JO, Murray RJ. Invasive *Streptococcus anginosus* group infection—does the species predict the outcome? *International Journal of Infectious Diseases*, 2014; 18: 38-40.
55. Chen X, Winckler B, Lu M, Cheng H, Yuan Z, Yang Y, Jin L, Ye W. Oral microbiota and risk for esophageal squamous cell carcinoma in a high-risk area of China. *PLoS One*, 2015; 10: e0143603.
56. Biarc J, Nguyen IS, Pini A, Gosse F, Richert S, Thierse D, Van Dorsselaer A, Leize-Wagner E, Raul F, Klein J-P. Carcinogenic properties of proteins with pro-inflammatory activity from *Streptococcus infantarius* (formerly *S. bovis*). *Carcinogenesis*, 2004; 25: 1477-1484.
57. Grant RJ, Whitehead TR, Orr JE. *Streptococcus bovis* meningitis in an infant. *Journal of clinical microbiology*, 2000; 38: 462-463.
58. Klein RS, Recco RA, Catalano MT, Edberg SC, Casey JI, Steigbigel NH. Association of *Streptococcus bovis* with carcinoma of the colon. *New England Journal of Medicine*, 1977; 297: 800-802.
59. McCoy W. Enterococcal endocarditis associated with carcinoma the sigmoid. *J Med Assoc State Ala*, 1951; 21: 162-165.
60. Gold JS, Bayar S, Salem RR. Association of *Streptococcus bovis* bacteremia with colonic neoplasia and extracolonic malignancy. *Archives of Surgery*, 2004; 139: 760-765.
61. Al-Jashamy K, Murad A, Zeehaida M, Rohaini M, Hasnan J. Prevalence of colorectal cancer associated with *Streptococcus bovis* among inflammatory bowel and chronic gastrointestinal tract disease patients. *Asian Pac J Cancer Prev*, 2010; 11: 1765-8.
62. Corredoira J, Coira A, Iñiguez I, Pita J, Varela J, Alonso M. Advanced intestinal cancer associated with *Streptococcus infantarius* (former *S. bovis* II/1) sepsis. *International journal of clinical practice*, 2013; 67: 1358-1359.
63. Blasi F, Tarsia P, Aliberti S. *Chlamydophila pneumoniae*. *Clinical Microbiology and Infection*, 2009; 15: 29-35.
64. Cudmore SL, Garber GE. Prevention or treatment: the benefits of *Trichomonas vaginalis* vaccine. *Journal of infection and public health*, 2010; 3: 47-53.
65. Organization WH. International Health Regulations : Notifications of diseases received from 16 to 22 January 2004. *Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire*, 2004; 79: 40-40.